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Definition

Significance of
Pathophysiology

Underlying Pathophysiology

Malignant hyperthermia (MH) is an autosomal-dominant disorder that is
inherited. The disturbance of calcium homeostasis associated with MH affects
skeletal muscle (Schneiderbanger, Johannsen, Roewer, & Schuster, 2014). This
hypermetabolic muscular disorder is triggered by exposure to depolarizing
muscle relaxants such as succinylcholine or inhaled halogenated volatile
anesthetics such as sevoflurane, halothane, desflurane, enflurane, and isoflurane
(Stratman, Flynn, & Hatton, 2009). In susceptible individuals, this potentially
lethal syndrome may cause hyperthermia, hypercapnia, muscular rigidity,
hypoxemia, acidosis, tachycardia, and hyperkalemia (Schneiderbanger et al.,
2014).

Relevance
MH occurs more often in children and young adults than in the adult population.
MH occurs more often in adult males than adult females. Distribution across
ethnicities occurs in equal proportions (Stratman et al., 2009). While a link
between MH and numerous myopathies is suspected, a predisposition has only
been identified in Evans myopathy, central-core disease, and King-Denborough
syndrome (Stratman et al., 2009).
Although MH is a rare inherited disorder, this potentially life-threatening
inherited disorder may occur approximately once in every 3,000 procedures
involving general anesthesia (Beggs, McCann, & Powers, 2012). While obtaining
thorough patient and family histories related to anesthesia events will reduce
occurrences of MH, many individuals are unaware of their own predisposition to
this disorder and relevant family histories. More efficient treatment of MH and
improved understanding of the pathophysiology related to this disorder have
resulted in an 11.7% decline in the mortality rate from MH from 2000 to 2005
(Johns, Stoudt, Scholtis, & Gavel, 2012).

Individuals with MH have a mutation of the ryanodine receptor
subtype 1 (RYR1) gene on chromosome 19q 13.1-13.2 (Li,
Brady, Rosenberg, & Sun, 2011; Thomas & Crowhurst, 2013).
When the dysfunctional receptor is exposed to triggering
agents, such as halogenated volatile anesthetics and
succinylcholine, a depolarizing neuromuscular blocking agent,
the prolonged opening of this dysfunctional receptor occurs
and results in the uncontrolled release of calcium within the
skeletal muscle sarcoplasmic reticulum causing a
hypermetabolic state in the susceptible individual (Kim, 2012).
As a result of this uncontrolled release of calcium and
continuous muscle activation, muscle rigidity occurs. As these
events continue, cellular adenosine triphosphate is depleted
resulting in protracted muscular rigidity and eventually
rhabdomyolysis. Rhabdomyolysis occurs when cell contents
such as creatine phosphokinase, potassium, and myoglobin are
released into circulation due to the deterioration of the cell
membrane. Also, in a MH event, oxygen consumption is
increased due to the continuous activation of aerobic and
anaerobic metabolism. This increase in oxygen consumption
results in acidosis, hypoxia, increased body temperature, and
excessive production of CO2 (Schneiderbanger et al., 2014).
Figure 1 illustrates the pathophysiological changes that occur
during a malignant hyperthermia event.

The following physiologic manifestations are linked to MH:
1. Muscular rigidity most often involving the masseter:
results from the uncontrolled and ongoing release of
calcium from the sarcoplasmic reticulum (Schuster,
Johannsen, Schneiderbanger, & Roewer, 2013).
2. Hyperthermia: results from the increased use of
adenosine triphosphate combined with the constricting
peripheral vasculature. The body’s ability to dissipate heat
is markedly impaired (Schneiderbanger et al., 2014).
3. Increased ETCO2: results from an increase in myoplasmic
calmodulin-dependent protein kinase (Ca2+). An
unexplained increase in ETCO2 is a common and early sign
of MH in mechanically ventilated and intubated patients
(Kim, 2012).
4. Acidosis: respiratory acidosis results from increased CO2
levels. Metabolic acidosis results from increased lactate
levels (Dirksen et al., 2013).
5. Myoglobinuria: results from damage to the cell
membrane allowing intracellular contents, such as
magnesium, potassium, creatine, and myoglobin to seep
into the bloodstream (Dirksen et al., 2013).
6. Renal Failure: due to cell membrane damage, released
myoglobin obstructs renal tubules causing acute renal
failure (Kim, 2012).

Implications for
Nursing Care

Signs & Symptoms


Table 1 Clinical signs of malignant hyperthermia
(Schneiderbanger et al., 2014, p.358)

Late
Hyperthermia
Rhabdomyolysis
Acute renal failure
Cardiac arrhythmia
Hypotension
Circulatory failure

Figure 2 Personnel roles and treatment interventions in a MH event
(Seifert et al., 2014, p. 197)

7. Tachycardia/tachypnea: Excessive amounts of CO2
(hypercarbia) and excessive K (hyperkalemia) in the blood
stimulate the sympathetic nervous system resulting in
rapid heart rate and/or rapid breathing
(Dirksen et al., 2013).
8. Cardiac arrhythmias/failure: Potentially fatal
dysrhythmias occur due to hyperkalemia and the kidneys
inability to excrete excess K (Dirksen et al., 2013).

However, to further improve outcomes for patients with malignant
hyperthermia, it is imperative for multidisciplinary medical team members to
promptly recognize early symptoms of MH, accurately diagnose this disorder,
and respond swiftly with the appropriate treatment (Dirksen, Van Wicklin,
Mashman, Neiderer, & Merritt, 2013).

Early
Masseter spasm
Generalized muscular rigidity
Tachycardia (>80%)
Hypercapnia
Hypoxia
Combined metabolicrespiratory acidosis

Implications for Nursing Care

Figure 1 Pathophysiologic changes during a
MH event (Schneiderbanger
et al., 2014 p. 357)

MH treatment objectives: stop the abnormal
metabolic reaction with dantrolene and restore
normal hemodynamic conditions, temperatures,
and metabolic functions. (Seifert, Wahr, Pace,
Cochrane, Bagnola, 2014)



Recommended management approach: Utilize a
multidisciplinary medical team trained to promptly
and accurately diagnose MH, work cooperatively,
understand multiple roles and responsibilities, and
efficiently utilize readily available equipment and
medications; medical teams should periodically
review MH protocol and participate in mock drills
to practice tasks and roles (Dirksen, 2013)



See Figure 2 for recommended roles and treatment

Conclusions
The ultimate goal is to prevent the occurrence of MH. As discussed by Beggs,
McCann, and Powers (2012), prior to the administration of anesthesia, obtaining
thorough patient and family histories related to adverse anesthesia reactions may
alert the anesthesia provider to the patient’s possible predisposition to MH and
dictate the selection of non-triggering MH anesthesia agents. However, when
prevention is not realized, continued vigilance and crisis preparedness on the part of
multidisciplinary medical team members will further reduce the MH mortality rate
and improve patient outcomes (Schneiderbanger et al., 2014).
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